thus , although further studies in giant papillary conjunctivitis and comparative studies with corticosteroids in allergic conjunctivitis and vernal keratoconjunctivitis are needed to more clearly define the extent of benefits that may be obtained from ocular sodium cromoglycate , it is clear that the safety and efficacy of the drug in type i allergic eye diseases is such that it should be considered as a first-line agent when drug therapy of these disorders is indicated .
C0009766
allergic conjunctivitis
C0015392
eye